Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Oct;68(4):691–694. doi: 10.1038/bjc.1993.411

MDR1 gene expression in primary colorectal carcinomas.

R Pirker 1, J Wallner 1, A Gsur 1, M Götzl 1, S Zöchbauer 1, W Scheithauer 1, D Depisch 1
PMCID: PMC1968613  PMID: 8398695

Abstract

The expression of the MDR1 gene, a multidrug resistance gene, was prospectively determined in 113 primary colorectal carcinoma specimens and correlated with clinical data including survival durations of the patients. MDR1 RNA was detected in 65% of the carcinomas. No expression of the MDR2 gene was seen, MDR1 gene expression was independent of age and sex of the patients, size and histologic grading of the tumour, lymph node involvement and distant metastasis. Kaplan-Meier analysis revealed that the durations of both relapse-free survival and overall survival were not different between patients with MDR1 RNA positive tumours and those with MDR1 RNA negative tumours.

Full text

PDF
691

Images in this article

692Figure 1
on p.692

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bell D. R., Gerlach J. H., Kartner N., Buick R. N., Ling V. Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol. 1985 Mar;3(3):311–315. doi: 10.1200/JCO.1985.3.3.311. [DOI] [PubMed] [Google Scholar]
  2. Campos L., Guyotat D., Archimbaud E., Calmard-Oriol P., Tsuruo T., Troncy J., Treille D., Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood. 1992 Jan 15;79(2):473–476. [PubMed] [Google Scholar]
  3. Chan H. S., Haddad G., Thorner P. S., DeBoer G., Lin Y. P., Ondrusek N., Yeger H., Ling V. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med. 1991 Dec 5;325(23):1608–1614. doi: 10.1056/NEJM199112053252304. [DOI] [PubMed] [Google Scholar]
  4. Chan H. S., Thorner P. S., Haddad G., Ling V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol. 1990 Apr;8(4):689–704. doi: 10.1200/JCO.1990.8.4.689. [DOI] [PubMed] [Google Scholar]
  5. Dalton W. S., Grogan T. M., Meltzer P. S., Scheper R. J., Durie B. G., Taylor C. W., Miller T. P., Salmon S. E. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol. 1989 Apr;7(4):415–424. doi: 10.1200/JCO.1989.7.4.415. [DOI] [PubMed] [Google Scholar]
  6. Fojo A. T., Shen D. W., Mickley L. A., Pastan I., Gottesman M. M. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol. 1987 Dec;5(12):1922–1927. doi: 10.1200/JCO.1987.5.12.1922. [DOI] [PubMed] [Google Scholar]
  7. Fojo A. T., Ueda K., Slamon D. J., Poplack D. G., Gottesman M. M., Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A. 1987 Jan;84(1):265–269. doi: 10.1073/pnas.84.1.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gerlach J. H., Bell D. R., Karakousis C., Slocum H. K., Kartner N., Rustum Y. M., Ling V., Baker R. M. P-glycoprotein in human sarcoma: evidence for multidrug resistance. J Clin Oncol. 1987 Sep;5(9):1452–1460. doi: 10.1200/JCO.1987.5.9.1452. [DOI] [PubMed] [Google Scholar]
  9. Goldstein L. J., Galski H., Fojo A., Willingham M., Lai S. L., Gazdar A., Pirker R., Green A., Crist W., Brodeur G. M. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989 Jan 18;81(2):116–124. doi: 10.1093/jnci/81.2.116. [DOI] [PubMed] [Google Scholar]
  10. Gottesman M. M., Pastan I. The multidrug transporter, a double-edged sword. J Biol Chem. 1988 Sep 5;263(25):12163–12166. [PubMed] [Google Scholar]
  11. Marie J. P., Zittoun R., Sikic B. I. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood. 1991 Aug 1;78(3):586–592. [PubMed] [Google Scholar]
  12. Pastan I., Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med. 1987 May 28;316(22):1388–1393. doi: 10.1056/NEJM198705283162207. [DOI] [PubMed] [Google Scholar]
  13. Pirker R., Goldstein L. J., Ludwig H., Linkesch W., Lechner C., Gottesman M. M., Pastan I. Expression of a multidrug resistance gene in blast crisis of chronic myelogenous leukemia. Cancer Commun. 1989;1(2):141–144. doi: 10.3727/095535489820875354. [DOI] [PubMed] [Google Scholar]
  14. Pirker R., Keilhauer G., Raschack M., Lechner C., Ludwig H. Reversal of multi-drug resistance in human KB cell lines by structural analogs of verapamil. Int J Cancer. 1990 May 15;45(5):916–919. doi: 10.1002/ijc.2910450523. [DOI] [PubMed] [Google Scholar]
  15. Pirker R., Wallner J., Geissler K., Linkesch W., Haas O. A., Bettelheim P., Hopfner M., Scherrer R., Valent P., Havelec L. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst. 1991 May 15;83(10):708–712. doi: 10.1093/jnci/83.10.708. [DOI] [PubMed] [Google Scholar]
  16. Riordan J. R., Deuchars K., Kartner N., Alon N., Trent J., Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. 1985 Aug 29-Sep 4Nature. 316(6031):817–819. doi: 10.1038/316817a0. [DOI] [PubMed] [Google Scholar]
  17. Roninson I. B., Chin J. E., Choi K. G., Gros P., Housman D. E., Fojo A., Shen D. W., Gottesman M. M., Pastan I. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4538–4542. doi: 10.1073/pnas.83.12.4538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Thiebaut F., Tsuruo T., Hamada H., Gottesman M. M., Pastan I., Willingham M. C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7735–7738. doi: 10.1073/pnas.84.21.7735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Twentyman P. R. MDR1 (P-glycoprotein) gene expression--implications for resistance modifier trials. J Natl Cancer Inst. 1992 Oct 7;84(19):1458–1460. doi: 10.1093/jnci/84.19.1458. [DOI] [PubMed] [Google Scholar]
  20. Wallner J., Depisch D., Gsur A., Götzl M., Haider K., Pirker R. MDR1 gene expression and its clinical relevance in primary gastric carcinomas. Cancer. 1993 Feb 1;71(3):667–671. doi: 10.1002/1097-0142(19930201)71:3<667::aid-cncr2820710303>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  21. Weinstein R. S., Jakate S. M., Dominguez J. M., Lebovitz M. D., Koukoulis G. K., Kuszak J. R., Klusens L. F., Grogan T. M., Saclarides T. J., Roninson I. B. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res. 1991 May 15;51(10):2720–2726. [PubMed] [Google Scholar]
  22. Weinstein R. S., Kuszak J. R., Kluskens L. F., Coon J. S. P-glycoproteins in pathology: the multidrug resistance gene family in humans. Hum Pathol. 1990 Jan;21(1):34–48. doi: 10.1016/0046-8177(90)90073-e. [DOI] [PubMed] [Google Scholar]
  23. Wishart G. C., Plumb J. A., Going J. J., McNicol A. M., McArdle C. S., Tsuruo T., Kaye S. B. P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer. 1990 Nov;62(5):758–761. doi: 10.1038/bjc.1990.373. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES